edoxaban + aspirin

Edoxaban + aspirin is a dual antithrombotic therapy combining a direct oral anticoagulant (**edoxaban**), which inhibits factor Xa to prevent thrombin generation and blood clot formation, with **aspirin**, an antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1) and suppresses thromboxane A2 production, reducing platelet aggregation. This combination is investigated for its safety and efficacy in preventing restenosis/reocclusion and thrombotic events after procedures like endovascular treatment in peripheral artery disease (PAD)[1][3]. While it targets both platelet and fibrin components of arterial thrombi, it is associated with an increased risk of major bleeding compared to monotherapy, and careful patient selection and monitoring are essential[2][3].

Other names

edoxaban + acetylsalicylic acid